News

The study was designed to determine whether the company’s proprietary substance, Homspera, is effaceable in blocking the development of airway hyperreactivity. The results indicate that Homespera could be

According to a statement from Mylan Laboratories, this decision comes as, following discussions, the two companies were “not able to agree upon terms for a revised transaction”. Mylan

The approval of Pegasys (peginterferon alfa-2a) in combination with Copegus (ribavirin, USP) for the treatment of hepatitis C in HIV patients was based on results from the largest

The phase III study showed that administering Neulasta (pegfilgrastim), beginning in the first and subsequent cycles of chemotherapy, reduced the incidence of febrile neutropenia (low white blood cell

The study of the compound, a partial agonist of the nicotinic alpha-7 receptor, is being conducted in Toronto, Canada, under a clinical trial application that Memory Pharmaceuticals filed

Mylan Bertek was notified by the FDA that the regulator has extended the original ten month Prescription Drug User Fee Act (PDUFA) deadline for the completion of its

Both companies share a common focus on priority R&D categories including cardiovascular, antibacterial, glucose metabolic, bone disorders, immune disorders and anti-allergy. Integration will enable increased concentration of R&D

Idun is focused on the discovery and development of therapies to control apoptosis, a process of cell death that occurs in a broad range of diseases. The company

Under the terms of the agreement, FDC will develop and manufacture the ophthalmic product and Spectrum Pharmaceuticals will be responsible for all regulatory, marketing and distribution matters in